Burning Rock Biotech (NASDAQ:BNR) Director Yusheng Han Acquires 24,900 Shares

Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) Director Yusheng Han bought 24,900 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were acquired at an average price of $8.00 per share, for a total transaction of $199,200.00. Following the acquisition, the director directly owned 18,404,086 shares of the company’s stock, valued at approximately $147,232,688. The trade was a 0.14% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Yusheng Han also recently made the following trade(s):

• On Wednesday, June 24th, Yusheng Han bought 250,000 shares of Burning Rock Biotech stock. The shares were bought at an average price of $8.00 per share, for a total transaction of $2,000,000.00.
• On Tuesday, June 23rd, Yusheng Han acquired 5,990 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $7.50 per share, for a total transaction of $44,925.00.
• On Monday, June 22nd, Yusheng Han purchased 104,650 shares of Burning Rock Biotech stock. The stock was purchased at an average price of $7.45 per share, for a total transaction of $779,642.50.
• On Tuesday, June 16th, Yusheng Han bought 111,110 shares of Burning Rock Biotech stock. The stock was acquired at an average cost of $9.00 per share, for a total transaction of $999,990.00.
• On Friday, June 12th, Yusheng Han acquired 210,000 shares of Burning Rock Biotech stock. The stock was acquired at an average cost of $9.25 per share, for a total transaction of $1,942,500.00.
• On Thursday, June 11th, Yusheng Han acquired 24,760 shares of Burning Rock Biotech stock. The shares were bought at an average cost of $8.74 per share, with a total value of $216,402.40.

Burning Rock Biotech Price Performance

Burning Rock Biotech stock opened at $8.96 on Thursday. The firm has a market capitalization of $94.26 million, a P/E ratio of -10.93 and a beta of 1.33. Burning Rock Biotech Limited Sponsored ADR has a 1 year low of $3.22 and a 1 year high of $41.72. The business has a 50-day moving average of $12.79 and a 200-day moving average of $20.08. The company has a current ratio of 3.05, a quick ratio of 2.81 and a debt-to-equity ratio of 0.06.

Burning Rock Biotech (NASDAQ:BNR) last released its quarterly earnings data on Tuesday, June 9th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($2.29) by $2.09. The business had revenue of $15.66 million during the quarter, compared to analysts’ expectations of $19.21 million. Burning Rock Biotech had a negative net margin of 11.57% and a negative return on equity of 10.98%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Crcm LP increased its holdings in shares of Burning Rock Biotech by 13.8% during the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after acquiring an additional 26,809 shares during the last quarter. Prospera Financial Services Inc lifted its holdings in Burning Rock Biotech by 26.0% during the 4th quarter. Prospera Financial Services Inc now owns 31,185 shares of the company’s stock valued at $628,000 after purchasing an additional 6,430 shares during the last quarter. Marshall Wace LLP acquired a new stake in Burning Rock Biotech during the 4th quarter valued at $220,000. Finally, Renaissance Technologies LLC boosted its position in Burning Rock Biotech by 13.8% during the first quarter. Renaissance Technologies LLC now owns 35,407 shares of the company’s stock worth $571,000 after purchasing an additional 4,290 shares during the period. 30.03% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

BNR has been the subject of several recent research reports. Wall Street Zen cut shares of Burning Rock Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.